CD274 and non-small cell lung carcinoma: Check-Mate 017 and Check-Mate 057 studies demonstrate that PD-L1 expression is positively associated with a greater overall survival (OS) profit from nivolumab in NSCLC patients with ≥50% PD-L1 expression; however, an effective response is still observed in patients with ≤1% PD-L1 expression (12).